Education
About Us
Working with TipRanks
Follow Us
Renovaro Biosciences Inc. (RENB)
:RENB
Total Valuation
Renovaro Biosciences has a market cap or net worth of $60.61M. The enterprise value is ―.
Market Cap$60.61M
Enterprise Value―
Share Statistics
Renovaro Biosciences has 162,392,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding162,392,910
Owned by Insiders41.95%
Owned by Institutions0.21%
Financial Efficiency
Renovaro Biosciences’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -60.13%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-60.13%
Return on Capital Employed (ROCE)-0.61
Revenue Per Employee0.00
Profits Per Employee-3.23M
Employee Count25
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Renovaro Biosciences is -1.86. Renovaro Biosciences’s PEG ratio is -0.10.
PE Ratio-1.86
PS Ratio―
PB Ratio1.14
Price to Fair Value1.14
Price to FCF-13.60
Price to Operating Cash Flow-13.69
PEG Ratio-0.10
Income Statement
In the last 12 months, Renovaro Biosciences had revenue of 0.00 and earned -80.65M in profits. Earnings per share was -0.84.
Revenue0.00
Gross Profit-121.86K
Operating Income-81.64M
Pretax Income-80.65M
Net Income-80.65M
EBITDA-79.52M
Earnings Per Share (EPS)-0.84
Cash Flow
In the last 12 months, operating cash flow was -11.64M and capital expenditures -28.85K, giving a free cash flow of -11.67M billion.
Operating Cash Flow-11.64M
Free Cash Flow-11.67M
Free Cash Flow per Share-0.07
Dividends & Yields
Renovaro Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.08
52-Week Price Change-76.28%
50-Day Moving Average0.66
200-Day Moving Average0.77
Relative Strength Index (RSI)36.04
Average Volume (3m)749.95K
Important Dates
Renovaro Biosciences upcoming earnings date is May 15, 2023, TBA Not Confirmed.
Last Earnings DateFeb 13, 2023
Next Earnings DateMay 15, 2023
Ex-Dividend Date―
Financial Position
Renovaro Biosciences as a current ratio of 0.07, with Debt / Equity ratio of 7.76%
Current Ratio0.07
Quick Ratio0.07
Debt to Market Cap0.02
Net Debt to EBITDA-0.04
Interest Coverage Ratio-80.73
Taxes
In the past 12 months, Renovaro Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Renovaro Biosciences EV to EBITDA ratio is -1.93, with an EV/FCF ratio of -13.92.
EV to Sales0.00
EV to EBITDA-1.93
EV to Free Cash Flow-13.92
EV to Operating Cash Flow-14.01
Balance Sheet
Renovaro Biosciences has $311.76K in cash and marketable securities with $5.00K in debt, giving a net cash position of $6.05M billion.
Cash & Marketable Securities$311.76K
Total Debt$5.00K
Net Cash$6.05M
Net Cash Per Share$0.04
Tangible Book Value Per Share-$0.28
Margins
Gross margin is 33.30%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin33.30%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Renovaro Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―